RE:G12C/G12V KRAS mutation in PC & CRC patients respond to PelaIf I was able to figure out pelareorep's MOA in pancreatic and CRC cancer ... I am sure that Big Pharma has also, which leads me to believe that it's all about the offer price for ONCY. The first offer should trigger a succession of other bids, and rest will be history in the acquisition of ONCY.